Feb 6 (Reuters) - Priovant:
* PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)
* PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
* PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA Source text: Further company coverage: (ROIV.O)

<p>Feb 6 (Reuters) - Priovant:* PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)* PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS* PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA Source text: Further company coverage:</p>

Reuters

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

Invesco Biotechnology & Genome ETF

Roivant Sciences

Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)